scholarly journals Unlocking the Paradoxical Endogenous Stem Cell Response after Spinal Cord Injury

Stem Cells ◽  
2019 ◽  
Author(s):  
Laureen D. Hachem ◽  
Andrea J. Mothe ◽  
Charles H. Tator
Keyword(s):  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Stem Cell ◽  
Cell Response ◽  
Cord Injury ◽  
Endogenous Stem Cell

scholarly journals Endogenous Proliferation after Spinal Cord Injury in Animal Models

2012 ◽  
Vol 2012 ◽  
pp. 1-16 ◽  
Author(s):  
Ashley McDonough ◽  
Verónica Martínez-Cerdeño
Keyword(s):  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Stem Cell ◽  
Animal Models ◽  
Cell Response ◽  
Cell Manipulation ◽  
Initial Increase ◽  
Cord Injury ◽  
Type Of Injury ◽  
Similar Peak

Spinal cord injury (SCI) results in motor and sensory deficits, the severity of which depends on the level and extent of the injury. Animal models for SCI research include transection, contusion, and compression mouse models. In this paper we will discuss the endogenous stem cell response to SCI in animal models. All SCI animal models experience a similar peak of cell proliferation three days after injury; however, each specific type of injury promotes a specific and distinct stem cell response. For example, the transection model results in a strong and localized initial increase of proliferation, while in contusion and compression models, the initial level of proliferation is lower but encompasses the entire rostrocaudal extent of the spinal cord. All injury types result in an increased ependymal proliferation, but only in contusion and compression models is there a significant level of proliferation in the lateral regions of the spinal cord. Finally, the fate of newly generated cells varies from a mainly oligodendrocyte fate in contusion and compression to a mostly astrocyte fate in the transection model. Here we will discuss the potential of endogenous stem/progenitor cell manipulation as a therapeutic tool to treat SCI.

Stem Cell Transplantation: A Promising Therapy for Spinal Cord Injury

2020 ◽  
Vol 15 (4) ◽  
pp. 321-331 ◽  
Author(s):  
Zhe Gong ◽  
Kaishun Xia ◽  
Ankai Xu ◽  
Chao Yu ◽  
Chenggui Wang ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Stem Cells ◽  
Spinal Cord Injury ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Therapeutic Potential ◽  
Embryonic Stem ◽  
Current Status ◽  
Cord Injury

Spinal Cord Injury (SCI) causes irreversible functional loss of the affected population. The incidence of SCI keeps increasing, resulting in huge burden on the society. The pathogenesis of SCI involves neuron death and exotic reaction, which could impede neuron regeneration. In clinic, the limited regenerative capacity of endogenous cells after SCI is a major problem. Recent studies have demonstrated that a variety of stem cells such as induced Pluripotent Stem Cells (iPSCs), Embryonic Stem Cells (ESCs), Mesenchymal Stem Cells (MSCs) and Neural Progenitor Cells (NPCs) /Neural Stem Cells (NSCs) have therapeutic potential for SCI. However, the efficacy and safety of these stem cellbased therapy for SCI remain controversial. In this review, we introduce the pathogenesis of SCI, summarize the current status of the application of these stem cells in SCI repair, and discuss possible mechanisms responsible for functional recovery of SCI after stem cell transplantation. Finally, we highlight several areas for further exploitation of stem cells as a promising regenerative therapy of SCI.

Pentapeptide IKVAV-engineered hydrogels for neural stem cell attachment

2021 ◽  
Author(s):  
Yixia Yin ◽  
Wenwu Wang ◽  
Qi Shao ◽  
Binbin Li ◽  
Dan Yu ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Stem Cell ◽  
Neural Stem Cell ◽  
Cell Attachment ◽  
Injury Repair ◽  
Cord Injury ◽  
Proliferation Ability

A IKVAV-functionalized hydrogel is developed. It not only enhances neural stem cell (NSC) attachment, growth, and differentiation, but also maintains the proliferation ability of the NSC spheroids in the hydrogel for spinal cord injury repair.

scholarly journals Transplanted Human Stem Cell-Derived Interneuron Precursors Mitigate Mouse Bladder Dysfunction and Central Neuropathic Pain after Spinal Cord Injury

2016 ◽  
Vol 19 (4) ◽  
pp. 544-557 ◽  
Author(s):  
Thomas M. Fandel ◽  
Alpa Trivedi ◽  
Cory R. Nicholas ◽  
Haoqian Zhang ◽  
Jiadong Chen ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Neuropathic Pain ◽  
Stem Cell ◽  
Bladder Dysfunction ◽  
Human Stem Cell ◽  
Central Neuropathic Pain ◽  
Cord Injury

scholarly journals Role of Neuregulin-1/ErbB Signaling in Stem Cell Therapy for Spinal Cord Injury-Induced Chronic Neuropathic Pain

Stem Cells ◽  
2012 ◽  
Vol 31 (1) ◽  
pp. 83-91 ◽  
Author(s):  
Feng Tao ◽  
Qun Li ◽  
Su Liu ◽  
Haiying Wu ◽  
John Skinner ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Neuropathic Pain ◽  
Stem Cell ◽  
Cell Therapy ◽  
Chronic Neuropathic Pain ◽  
Neuregulin 1 ◽  
Cord Injury ◽  
Erbb Signaling

scholarly journals Safety and Feasibility of Autologous Olfactory Ensheathing Cell and Bone Marrow Mesenchymal Stem Cell Co-transplantation in Chronic Human Spinal Cord Injury: A Clinical Trial

2021 ◽  
Author(s):  
Homa Zamani ◽  
Mina Soufizomorrod ◽  
Saeed Oraee-Yazdani ◽  
Dariush Naviafar ◽  
Mohammadhosein Akhlaghpasand ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Bone Marrow ◽  
Spinal Cord Injury ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Safety Issue ◽  
Functional Evaluation ◽  
Olfactory Ensheathing Cell ◽  
Human Spinal Cord ◽  
Cord Injury

Abstract Cell-based therapies are considered as promising strategies for spinal cord regeneration. However, a combinatorial cell therapeutic approach seems more beneficial as it can target various aspects of the injury. Here, we assessed the safety and feasibility of autologous mucosal Olfactory Ensheathing Cell (OEC) and bone marrow Mesenchymal Stem Cell (MSC) co-transplantation in patients with chronic, complete (American Spinal Injury Association (ASIA) classification A) Spinal Cord Injury (SCI). Three patients with the traumatic SCI of the thoracic level were enrolled. They received autologous OEC and MSC combination through the lumbar puncture. All adverse events and possible functional outcomes were documented performing pre- and post-operative general clinical examination, Magnetic Resonance Imaging (MRI), neurological assessment based on the International Standard of Neurological Classification for SCI (ISNCSCI), and functional evaluation using Spinal Cord Independence Measure version III (SCIM III). No serious safety issue was recorded during the two years of follow-up. MRI findings remained unchanged with no neoplastic tissue formation. ASIA impairment scale improved from A to B in one of the participants. SCIM III evaluation also showed some degrees of progress in this patient's quality of life. The two other patients had negligible or no improvement in their sensory scores without any changes in the ASIA impairment scale and SCIM III scores. No motor recovery was observed in any of the participants. Overall, this two-year trial was not associated with any adverse findings, which may suggest the safety of autologous OEC and bone marrow MSC combination for the treatment of human SCI.This study was registered at the Iranian Registry of Clinical Trials (IRCT registration number: IRCT20160110025930N2/ registration date: 2018-09-29).

scholarly journals The Ethics of the Treatment of Spinal Cord Injury: Stem Cell Transplants, Motor Neuroprosthetics, and Social Equity

2008 ◽  
Vol 14 (1) ◽  
pp. 76-88 ◽  
Author(s):  
Jeffrey Rosenfeld ◽  
Prateek Bandopadhayay ◽  
Tony Goldschlager ◽  
Douglas Brown
Keyword(s):  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Stem Cell ◽  
Social Equity ◽  
Cord Injury ◽  
Cell Transplants ◽  
Stem Cell Transplants
Sign in / Sign up

Export Citation Format

Share Document